Key clinical point: The infective endocarditis risk following TAVR is virtually the same as with SAVR, so prescribe prophylactic antibiotics accordingly.
Major finding: The rate of infective endocarditis during slightly more than 2 years of follow-up was 1.89% per year in TAVR recipients and similar at 1.71% per year in patients who had undergone SAVR.
Study details: This retrospective French nationwide study included 16,291 patients who underwent an isolated TAVR during 2010-2018 and an equal number of SAVR patients exhaustively propensity-matched on 30 variables.
Disclosures: The presenter reported having no financial conflicts regarding the study, conducted free of commercial support. He serves as a consultant to and/or on speakers’ bureaus for Bayer, BMS Pfizer, Boehringer Ingelheim, Medtronic, and Novartis.
Fauchier L. ESC 2019, Abstract 5844.